Evidence map›Paper›PMID 28044213›Full record

Trial reportInternational journal of clinical oncology2017

Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.

Chih-Ching Yeh, Ching-Yu Lai, Shih-Ni Chang, Ling-Ling Hsieh, Reiping Tang, Fung-Chang Sung, Yi-Kuei Lin

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Targeting purine metabolism in ovarian cancer.Journal of ovarian research · 2022
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Chih-Ching YehSchool of Public Health, College of Public Health, Taipei Medical University, 250 Wu-Hsing Street, Taipei, 110, Taiwan. ccyeh@tmu.edu.tw.
Ching-Yu LaiSchool of Public Health, College of Public Health, Taipei Medical University, 250 Wu-Hsing Street, Taipei, 110, Taiwan.
Shih-Ni ChangManagement Office for Health Data, China Medical University Hospital, 2 Yude Road, Taichung, 404, Taiwan.
Ling-Ling HsiehDepartment of Public Health, Chang Gung University, 259 Wen-Hwa 1st Road, Guieshan, 333, Taoyuan, Taiwan.
Reiping TangColorectal Section, Chang Gung Memorial Hospital, 5 Fusing Street, Guieshan, 333, Taoyuan, Taiwan.
Fung-Chang SungManagement Office for Health Data, China Medical University Hospital, 2 Yude Road, Taichung, 404, Taiwan.
Yi-Kuei LinDepartment of Industrial Management, National Taiwan University of Science and Technology, 43, Sec. 4, Keelung Road, Taipei, 106, Taiwan.
Taipei Medical University · TWChang Gung Memorial Hospital · TWChang Gung University · TWChina Medical University · TWChina Medical University Hospital · TWNational Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan.

methodsWe genotyped MTHFR polymorphisms C677T (rs1801133) and A1298C (rs1801131) for 498 CRC patients treated with 5-FU-based chemotherapy after receiving surgery. Survival analyses on MTHFR polymorphisms were performed using log-rank test and Kaplan-Meier curve. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between MTHFR genotypes and survival.

resultsOverall survival (OS) was significantly longer in CRC patients with MTHFR 677 CT+TT genotypes compared with those with 677 CC genotype (HR 0.77; 95% CI 0.60-0.98). Although the MTHFR A1298C polymorphism was not associated with OS in CRC, this polymorphism was associated with significantly shorter OS in rectal cancer. Among rectal cancer patients, OS was shorter for patients with AC+CC genotypes than for those with the AA genotype (HR 1.95; 95% CI 1.35-2.83). In haplotype analysis, better OS was found for colon cancer patients carrying the MTHFR 677T-1298A haplotype (HR 0.73; 95% CI 0.55-0.97), but worse survival was linked to rectal cancer patients carrying the MTHFR 677C-1298C haplotype (HR 1.53; 95% CI 1.08-2.18).

conclusionsOur findings suggest that MTHFR genotypes provide prognostic information for CRC patients treated with 5-FU-based chemotherapy.

Indexed as

Polymorphism, Single NucleotideAgedColonic NeoplasmsColorectal NeoplasmsFemaleFluorouracilHaplotypesHumansMaleMethylenetetrahydrofolate Reductase (NADPH2)Middle AgedPrognosisProportional Hazards ModelsRectal NeoplasmsRetrospective StudiesSurvival AnalysisFluorouracilMethylenetetrahydrofolate Reductase (NADPH2)5-FluorouracilColorectal cancerMTHFROverall survivalPolymorphisms

Identifiers

PMID28044213
OpenAlexW2566616659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.